Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141308 · ClinicalTrials.gov registry record
OCT in Rare Chorioretinal Diseases
A clinical trial of Central Serous Chorioretinopathy and Retinal Artery Occlusions, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT02141308 is a study of Central Serous Chorioretinopathy and Retinal Artery Occlusions that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 150 participants, above the 59-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (154% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02141308, a study of Central Serous Chorioretinopathy and Retinal Artery Occlusions, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels. The purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.
Conditions Studied
Study Locations (1)
Oregon
- Casey Eye Institute, Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2014-05 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141308
The ClinicalTrials.gov registry entry for NCT02141308 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 59-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (154% higher). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 0 interventions.
NCT02141308 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT02141308 about?
NCT02141308 is a clinical study titled "OCT in Rare Chorioretinal Diseases". This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels. The purpose of measuring blood flow in the retina and choroid is to 1.) determi...
What is the current status of trial NCT02141308?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2014-05. Estimated completion is 2026-12.
What conditions does trial NCT02141308 study?
This clinical trial studies the following conditions: Central Serous Chorioretinopathy, Retinal Artery Occlusions, Polypoidal Choroidal Vasculopathy, Retinal Arterial Macroaneurysm, Juxtafoveal Telangiecasia.
Who is sponsoring clinical trial NCT02141308?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141308 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Serous Chorioretinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
Eplerenone for the Treatment of Central Serous Chorioretinopathy
COMPLETED · NA
-
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.